Abstract
Biofilms cause chronic infections that are difficult to treat because of the resistance of microorganisms inside them. The goal is to assess the killing potential of cefotaxime against Escherichia coli in biofilms obtained from clinical isolates kept in the clinical microbiology laboratory of Dr. Soetomo Surabaya Hospital. The study was conducted by laboratory experimental design. Two steps challenged the bacterial isolates by applying cefotaxime to the planktonic bacterial state and the biofilm state. Minimum inhibitory concentration (MIC), minimum biofilm inhibitory concentration (MBIC), minimum bactericidal concentration (MBC) and minimum biofilm eradication concentration (MBEC) were used as an indicator for comparison. Nineteen isolates of E coli were used for this experiment, 7 isolates with MIC of 0.125-0.25 μg/ml (36,84%), 6 isolates with MBC value 0.25-0.5 μg/ml (31,57%). The MBIC > 128 μg/ml is 6 isolates (31,57%), MBEC > 128 μg/ml is 14 isolates (73,68%). Cefotaxime had lower killing efficacy against E. coli in biofilm than in the planktonic phase. MBIC of E. coli requires cefotaxime at minimal 5 times two-fold increase from MIC, with an average 7-8 times. MBEC of E. coli requires cefotaxime concentration minimal 5 times two-fold dilution increase from MBC, with an average 8 - 9 times.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
